In addition, due to the limited number of patients in the present study, large-scale clinical trials are required to confirm the efficacy of CD19 CAR T- cell therapy as well as the combination of CD19 CAR T- cell therapy and allo-HSCT in CD19-positive R/R t(8;21) AML. Here, CD19 is linked to acute myeloid leukemia.